Arrowhead Pharmaceuticals 8-K Report: Key Developments on December 11, 2024

From the provided section of the financial report, here are the key insights and information extracted:

Entity Information:

Company Name: Arrowhead Pharmaceuticals, Inc.
CIK (Central Index Key): 0000879407
State of Incorporation: Delaware (DE)
Industry: Pharmaceuticals
Address: 177 E. Colorado Blvd, Suite 700, Pasadena, CA 91105
Phone Number: 626-304-3400

Filing Details:

Filing Type: 8-K (a form used to report major events that shareholders should know about)
Filing Date: December 11, 2024
SEC File Number: 001-38042

Stock Information:

Common Stock: The company has issued common stock with a par value of $0.001 per share.
Ticker Symbol: ARWR
Exchange: NASDAQ

Reporting Period:

Period of Report: The report covers a single day, December 11, 2024.

Insights:

Arrowhead Pharmaceuticals is actively engaging with investors and regulatory bodies by filing an 8-K, indicating that there may be significant developments or events requiring disclosure.
The company is publicly traded on NASDAQ, under the ticker ARWR, which is relevant for investors monitoring its market performance.
The specific focus on the single-day period may imply that the report addresses urgent updates or events that have immediate implications for the company or its share value.

This information can be critical for stakeholders assessing the company's current status, regulatory compliance, and any immediate actions or events that may impact investment decisions.